

Philippe R Lagacé©-Wiens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5184575/publications.pdf>

Version: 2024-02-01

71
papers

3,491
citations

236925

25
h-index

161849

54
g-index

102
all docs

102
docs citations

102
times ranked

3935
citing authors

#	ARTICLE	IF	CITATIONS
1	Ceftazidime-Avibactam: a Novel Cephalosporin/ β -Lactamase Inhibitor Combination. <i>Drugs</i> , 2013, 73, 159-177.	10.9	362
2	Imipenemâ€“Relebactam and Meropenemâ€“Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	10.9	291
3	Ceftolozane/Tazobactam: A Novel Cephalosporin/ β -Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2014, 74, 31-51.	10.9	279
4	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	10.9	274
5	Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1430-1437.	3.2	207
6	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	10.9	199
7	Identification of Blood Culture Isolates Directly from Positive Blood Cultures by Use of Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry and a Commercial Extraction System: Analysis of Performance, Cost, and Turnaround Time. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3324-3328.	3.9	173
8	Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. <i>Core Evidence</i> , 2014, 9, 13.	4.7	142
9	Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. <i>Drugs</i> , 2015, 75, 253-270.	10.9	140
10	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4684-4693.	3.2	138
11	Ceftaroline. <i>Drugs</i> , 2009, 69, 809-831.	10.9	114
12	<i>In Vitro</i> Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2554-2563.	3.2	107
13	Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3169-3175.	3.2	97
14	Adverse reactions to β -lactam antimicrobials. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 381-399.	2.4	87
15	Activity of NXL104 in Combination with β -Lactams against Genetically Characterized <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates Producing Class A Extended-Spectrum β -Lactamases and Class C β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2434-2437.	3.2	77
16	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , 2019, 155, 69-78.	0.8	67
17	Influenza epidemiologyâ€“past, present, and future. <i>Critical Care Medicine</i> , 2010, 38, e1-e9.	0.9	55
18	Prevalence and characterization of extended-spectrum β -lactamaseâ€“ and AmpC β -lactamaseâ€“producing <i>Escherichia coli</i> : results of the CANWARD 2007â€“2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 326-334.	1.8	55

#	ARTICLE	IF	CITATIONS
19	Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada. <i>Mycoses</i> , 2018, 61, 743-753.	4.0	50
20	Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 67-80.	1.8	49
21	<i>Dientamoeba fragilis</i> : an emerging role in intestinal disease. <i>Cmaj</i> , 2006, 175, 468-468.	2.0	36
22	Antimicrobial susceptibility of 2906 <i>Pseudomonas aeruginosa</i> clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 60-63.	1.8	36
23	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115012.	1.8	36
24	Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. <i>Peritoneal Dialysis International</i> , 2017, 37, 170-176.	2.3	35
25	Mechanisms of resistance and mobility among multidrug-resistant CTX-M β -producing <i>Escherichia coli</i> from Canadian intensive care units: the 1st report of QepA in North America. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 319-326.	1.8	34
26	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 645-653.	3.0	26
27	Frequency of MCR-1-mediated colistin resistance among <i>Escherichia coli</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). <i>CMAJ Open</i> , 2016, 4, E641-E645.	2.4	24
28	In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible <i>Pseudomonas aeruginosa</i> clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 703-708.	3.0	21
29	Mechanical valve endocarditis caused by <i>Gemella morbillorum</i> . <i>Journal of Medical Microbiology</i> , 2007, 56, 1689-1691.	1.8	20
30	Clonal Clusters and Virulence Factors of Group C and G <i>Streptococcus</i> Causing Severe Infections, Manitoba, Canada, 2012-2014. <i>Emerging Infectious Diseases</i> , 2017, 23, 1079-1088.	4.3	20
31	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2021, 81, 233-256.	10.9	20
32	<i>Pasteurella</i> Species Peritoneal Dialysis-Associated Peritonitis: Household Pets as a Risk Factor. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 52-55.	1.9	19
33	Changing trends in β -hemolytic streptococcal bacteremia in Manitoba, Canada: 2007-2012. <i>International Journal of Infectious Diseases</i> , 2014, 28, 211-213.	3.3	17
34	Real-life experience with ceftobiprole in Canada: Results from the CLEAR (Canadian Leadership) Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, 1079-1088.	2.2	17
35	A Case of Vertical Transmission of Chagas Disease Contracted via Blood Transfusion in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 32-34.	1.9	16
36	Characterization of isolates of <i>Eisenbergiella tayi</i> , a strictly anaerobic Gram-stain variable bacillus recovered from human clinical materials in Canada. <i>Anaerobe</i> , 2017, 44, 128-132.	2.1	15

#	ARTICLE	IF	CITATIONS
37	Seasonality of coronaviruses and other respiratory viruses in Canada: Implications for COVID-19. <i>Canada Communicable Disease Report</i> , 2021, 47, 132-138.	1.3	15
38	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 9A-19A.	1.9	14
39	In vitro susceptibility of urinary <i>Escherichia coli</i> isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007–2016. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 62-68.	2.5	14
40	Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF/MS)-Based Identification of Pathogens from Positive Blood Culture Bottles. <i>Methods in Molecular Biology</i> , 2015, 1237, 47-55.	0.9	14
41	Emerging group C and group G streptococcal endocarditis: A Canadian perspective. <i>International Journal of Infectious Diseases</i> , 2017, 65, 128-132.	3.3	13
42	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> , 2022, 82, 533-557.	10.9	12
43	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and <i>Pseudomonas aeruginosa</i> isolated from patients across Canada as part of the CANWARD study, 2016-2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115418.	1.8	8
44	Serologic testing for <i>Bartonella</i> in Manitoba, Canada, 2010–2020: a retrospective case series. <i>CMAJ Open</i> , 2022, 10, E476-E482.	2.4	8
45	Multifaceted antibiotic treatment analysis of methicillin-sensitive <i>Staphylococcus aureus</i> bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 674-679.	2.5	7
46	Antimicrobial susceptibility of <i>Pseudomonas aeruginosa</i> isolates obtained from patients in Canadian hospitals: CANWARD 2008–2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 361-364.	1.8	6
47	Quintessential Culture-Negative Endocarditis. <i>Canadian Journal of Cardiology</i> , 2016, 32, 395.e9-395.e10.	1.7	6
48	Endocarditis due to <i>Bartonella quintana</i> , the etiological agent of trench fever. <i>Cmaj</i> , 2020, 192, E1723-E1726.	2.0	5
49	Prevalence and Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Isolated in Canadian Hospitals: Results from CANWARD 2007. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 43A-48A.	1.9	3
50	Prevalence, predictors, and consequences of inappropriate empiric antimicrobial therapy for complicated urinary tract and intra-abdominal infections in Winnipeg hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114891.	1.8	3
51	Antimicrobial Susceptibility of 6685 Organisms Isolated from Canadian Hospitals: CANWARD 2007. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 20A-30A.	1.9	2
52	<i>Campylobacter concisus</i> gastritis masquerading as <i>Helicobacter pylori</i> on gastric biopsy. <i>Helicobacter</i> , 2022, 27, e12864.	3.5	2
53	Frailty Hinders Recovery From Acute Respiratory Illness in Older Adults. <i>Open Forum Infectious Diseases</i> , 2017, 4, S573-S574.	0.9	1
54	<i>Mycobacterium Mucogenicum</i> Bacteremia and Nodular Soft Tissue Infection in a Person Who Uses Tap Water to Inject Drugs. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa580.	0.9	1

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Hologic Aptima Combo 2 Assay for Detection of <i>Neisseria gonorrhoeae</i> from Joint Fluid Specimens. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0253021.	3.9	1
56	Cardiac Aspergillosis. , 2009, , 889-903.		0
57	254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. <i>Open Forum Infectious Diseases</i> , 2014, 1, S109-S109.	0.9	0
58	Hemorrhagic pustules in an Aboriginal man. <i>Cmaj</i> , 2014, 186, 607-610.	2.0	0
59	Su1153 Tissue Culture for <i>H. pylori</i> Is More Effective Than Rapid Urease Testing Alone, and Adds Minimal Cost to Testing. <i>Gastroenterology</i> , 2015, 148, S-422.	1.3	0
60	Group C and G Streptococci: An Emerging Cause of Endocarditis and Severe Infections in Manitoba, Canada. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
61	Quinolones. , 2017, , 1239-1248.e2.		0
62	In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 <i>Stenotrophomonas maltophilia</i> Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011-2016). <i>Open Forum Infectious Diseases</i> , 2017, 4, S367-S368.	0.9	0
63	In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008-2016. <i>Open Forum Infectious Diseases</i> , 2017, 4, S372-S372.	0.9	0
64	Impact of Antivirals in the Prevention of Serious Outcomes Associated with Influenza in Hospitalized Canadian Adults: A Pooled Analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). <i>Open Forum Infectious Diseases</i> , 2017, 4, S18-S18.	0.9	0
65	2383. <i>In Vitro</i> Activity of Ceftolozane-Tazobactam in Comparison With Ceftazidime-Avibactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007-2017. <i>Open Forum Infectious Diseases</i> . 2018, 5, S710-S710.	0.9	0
66	Marked elevation of serum ferritin associated with <i>Anaplasma phagocytophilum</i> infection. <i>Jammi</i> , 2019, 4, 37-41.	0.5	0
67	708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011-2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S319-S319.	0.9	0
68	128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S93-S93.	0.9	0
69	In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. <i>Jammi</i> , 2021, 6, 149-162.	0.5	0
70	In Vitro Activity of Colistin (Polymyxin E) Versus 2541 <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained From Patients in Canadian Hospitals: Results of the CANWARD Study, 2008-2014. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	0
71	Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007-2014. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, 266-271.	0.1	0